News

EuroPCR 2024: Elixir Medical’s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES

Clinical research comparing DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific antithrombotic therapeutic (TRx) coating versus a contemporary drug-eluting stent (DES), results demonstrated a statistically significant lower TLF rate with DESyne BDS Plus than DES.

EuroPCR 2024: Late-Breaking Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years

Clinical results show statistically significant benefit with DynamX bioadaptor over Resolute Onyx at two years, including a 65% reduction in TLF rate (1.9% versus 5.5%; p=0.046), driven by low adverse events across all components of the composite endpoint with DynamX compared to DES.

Elixir Medical To Announce Data from Three Platforms Designed to Transform Cardiovascular Disease Treatment at EuroPCR 2024, Including Two Late-Breakers

Researchers will present results from the BIOADAPTOR RCT, studying DynamX® bioadaptor vs. DES; PINNACLE I, which reviews the novel LithiX Hertz Contact Intravascular Lithotripsy technology; and one-year results from DESyne BDS Plus RCT, a study of the novel TRx site-specific antithrombotic therapeutic.

King Fahad Armed Forces Hospital Begins Trial of New Bioadaptive Angioplasty Procedure for Heart Disease Treatment

King Fahad Armed Forces Hospital is the first in the Kingdom of Saudi Arabia to begin clinical research and offer a new type of angioplasty procedure with the DynamX® Bioadaptor, a novel coronary implant designed to restore vessel function in patients with coronary artery disease (CAD).

Elixir Medical Receives FDA Breakthrough Device Designation for the DynamX BTK System for Use in the Treatment of Chronic Limb-Threatening Ischemia Resulting From Below-The-Knee Arterial Disease

Elixir Medical today announced it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its DynamX® BTK System.

TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy

Elixir Medical announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus versus a second-generation, durable polymer drug-eluting stent (DES).

Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023

Elixir Medical will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospective, multicenter, single-blind study, as part of The Innovation Program at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco